Reviewing Zai Lab (ZLAB) & Omeros (OMER)

Zai Lab (NASDAQ: ZLAB) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk.

Valuation & Earnings

This table compares Zai Lab and Omeros’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zai Lab N/A N/A -$37.51 million N/A N/A
Omeros $64.83 million 8.24 -$53.48 million ($1.18) -9.37

Zai Lab has higher earnings, but lower revenue than Omeros.


This table compares Zai Lab and Omeros’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zai Lab N/A N/A N/A
Omeros -82.50% N/A -40.03%

Insider and Institutional Ownership

21.0% of Zai Lab shares are owned by institutional investors. Comparatively, 48.6% of Omeros shares are owned by institutional investors. 12.1% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Zai Lab and Omeros, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zai Lab 0 0 3 0 3.00
Omeros 0 3 4 1 2.75

Zai Lab currently has a consensus price target of $37.00, indicating a potential upside of 78.74%. Omeros has a consensus price target of $29.72, indicating a potential upside of 168.68%. Given Omeros’ higher probable upside, analysts plainly believe Omeros is more favorable than Zai Lab.


Omeros beats Zai Lab on 6 of the 10 factors compared between the two stocks.

Zai Lab Company Profile

Zai Lab Ltd, incorporated on March 28, 2017, is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.

Omeros Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement. Omidria is derived from its PharmacoSurgery platform, which is designed for patients undergoing ophthalmological, arthroscopic, urological and other surgical procedures. Its PharmacoSurgery platform is based on low-dose combinations of the United States Food and Drug Administration (FDA) approved therapeutic agents delivered directly to the surgical site throughout the duration of the procedure to inhibit preemptively inflammation and other problems caused by surgical trauma, and to provide clinical assistances both during and after surgery.

Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with's FREE daily email newsletter.

Leave a Reply